Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
CAMBRIDGE, MA — (Marketwired) — 07/16/13 — (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote lecture titled "Translating Nanomedicine: Molecular medical devices from Nano Neuro Knitting to Imme